How to bridge the gap in Bt cotton cultivation

Updated on 21 May 2012

The Indian government must take a relook at its policies and programs to put the Bt cotton boom story back on track

How to bridge the gap in Bt cotton cultivation

New technologies, more stress on R&D and better procurement packages are needed to keep the Bt cotton growth story going

To keep pace with the growth story in cotton cultivation, the government needs to do more. New technologies, more stress on R&D and better procurement packages can go a long way in encouraging cultivation and improve market conditions.   

Dr Gyanendra Shukla, director, Mahyco Monsanto Biotech (MMB), says, "The cost of cultivation constitutes up to 60 percent of investment and seed price is only seven-to-eight percent of the total cost. Therefore, the seed price is a miniscule issue as the farmers may pay for a good seed that can give better yield." On the current requirements, he adds, "On the contrary, there is a requirement of new technology for further improvements of seed hybrids and the industry must be duly incentivized to bring down the cost of cultivation."

Due to shortage of Bt cotton seeds in previous years, the state governments have been asking for written commitment from the seed companies about their supply plans. Owing to factors such as rainfall and seasonal variations in Bt cotton arrivals, the prices of cotton get affected. Although a seed shortage is expected, seed prices may not go up because Gujarat, Maharashtra and Andhra Pradesh governments have fixed the prices through legislation. In other states, there is an indirect price control because state governments ask for undertakings from seed companies that they will not sell seeds above the maximum agreed price.

Bridging the gap

Improve technologies to increase yields: It is time now to move on and bring in other improved technologies such as sucking pest tolerance technology; drought resistance technologies; saline tolerance technologies; and weed management technologies

 

Previous 1

Leave a Reply

Notify me of follow-up comments via e-mail address

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X